Chongqing Zhifei Biological Products Co., Ltd. (SHE:300122)

Market Cap	46.49B
Revenue (ttm)	17.05B
Net Income (ttm)	255.59M
Shares Out	2.39B
EPS (ttm)	0.11
PE Ratio	181.98
Forward PE	31.09
Dividend	0.20 (1.03%)
Ex-Dividend Date	Dec 25, 2024

Volume	18,770,502
Average Volume	26,164,467
Open	19.10
Previous Close	19.35
Day's Range	19.10 - 19.70
52-Week Range	18.70 - 40.43
Beta	1.22
RSI	48.06
Earnings Date	Aug 29, 2025

About SHE:300122

Chongqing Zhifei Biological Products Co., Ltd. engages in the research and development, production, marketing, distribution, import, and export of vaccines in China. The company offers Recombinant Novel Coronavirus Vaccine (CHO Cell); Recombinant Mycobacterium Tuberculosis Fusion Protein under the Ekear brand; Haemophilus Influenzae Type b Vaccine under the XiFeiBei brand; ACYW135 Meningococcal Polysaccharide Vaccine under the Menwayc brand; Mycobacterium Vaccae for Injection under the Vaccae brand; Meningococcal Group A and Group C Polysacchar...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 7,220
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300122

Financial Performance

In 2024, SHE:300122's revenue was 26.07 billion, a decrease of -50.74% compared to the previous year's 52.92 billion. Earnings were 2.02 billion, a decrease of -74.99%.